Melin Janardan Khandekar, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 9 | 2022 | 13489 | 0.550 |
Why?
|
| PPAR gamma | 1 | 2018 | 484 | 0.470 |
Why?
|
| GATA2 Transcription Factor | 4 | 2008 | 158 | 0.470 |
Why?
|
| Thiazolidinediones | 1 | 2018 | 460 | 0.470 |
Why?
|
| Genital Neoplasms, Male | 1 | 2013 | 68 | 0.410 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2008 | 1366 | 0.370 |
Why?
|
| Liposarcoma | 1 | 2013 | 288 | 0.350 |
Why?
|
| Radiosurgery | 4 | 2022 | 1330 | 0.340 |
Why?
|
| DNA Damage | 1 | 2018 | 2469 | 0.290 |
Why?
|
| Cranial Irradiation | 2 | 2020 | 392 | 0.260 |
Why?
|
| Urogenital System | 2 | 2008 | 88 | 0.250 |
Why?
|
| Introns | 2 | 2008 | 966 | 0.240 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 329 | 0.240 |
Why?
|
| Radiation Injuries | 2 | 2023 | 1195 | 0.230 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2018 | 5690 | 0.230 |
Why?
|
| Endothelium | 1 | 2007 | 768 | 0.230 |
Why?
|
| Adipocytes | 5 | 2014 | 1196 | 0.220 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 9101 | 0.210 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 5389 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 13644 | 0.170 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2022 | 174 | 0.160 |
Why?
|
| Models, Immunological | 1 | 2022 | 517 | 0.160 |
Why?
|
| Lung Injury | 1 | 2023 | 432 | 0.160 |
Why?
|
| Thoracic Wall | 1 | 2020 | 203 | 0.150 |
Why?
|
| Thermogenesis | 2 | 2013 | 495 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2021 | 409 | 0.150 |
Why?
|
| Neoplasms | 5 | 2024 | 22350 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2021 | 9407 | 0.140 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 4 | 2020 | 1673 | 0.140 |
Why?
|
| DNA-Binding Proteins | 3 | 2014 | 9613 | 0.130 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2008 | 125 | 0.130 |
Why?
|
| Hippocampus | 2 | 2020 | 3776 | 0.130 |
Why?
|
| Chromosomes, Artificial, Yeast | 2 | 2007 | 113 | 0.130 |
Why?
|
| Organs at Risk | 1 | 2018 | 367 | 0.130 |
Why?
|
| Amino Acid Motifs | 1 | 2018 | 928 | 0.120 |
Why?
|
| Blood Vessels | 1 | 2021 | 1111 | 0.120 |
Why?
|
| Photons | 1 | 2019 | 591 | 0.120 |
Why?
|
| Transcription Factors | 4 | 2014 | 12159 | 0.120 |
Why?
|
| Viral Load | 1 | 2024 | 3385 | 0.120 |
Why?
|
| Models, Theoretical | 2 | 2024 | 3563 | 0.120 |
Why?
|
| Carboplatin | 1 | 2018 | 790 | 0.120 |
Why?
|
| Obesity | 3 | 2014 | 13090 | 0.110 |
Why?
|
| Adipose Tissue, Brown | 3 | 2014 | 776 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2021 | 1958 | 0.100 |
Why?
|
| Transgenes | 2 | 2008 | 1014 | 0.100 |
Why?
|
| Adipose Tissue | 3 | 2014 | 3317 | 0.100 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 1411 | 0.100 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 798 | 0.090 |
Why?
|
| Mice, Nude | 1 | 2018 | 3618 | 0.090 |
Why?
|
| TRPV Cation Channels | 1 | 2012 | 244 | 0.090 |
Why?
|
| Ligands | 1 | 2018 | 3274 | 0.090 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2011 | 279 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 1 | 2021 | 2631 | 0.090 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 3235 | 0.090 |
Why?
|
| Pericytes | 1 | 2012 | 298 | 0.080 |
Why?
|
| Mice | 12 | 2023 | 81898 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 11924 | 0.080 |
Why?
|
| Humans | 29 | 2024 | 766812 | 0.080 |
Why?
|
| Brachial Plexus | 1 | 2010 | 171 | 0.080 |
Why?
|
| Genome | 2 | 2008 | 1753 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1012 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2018 | 8310 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 1788 | 0.070 |
Why?
|
| Lung | 3 | 2023 | 10068 | 0.070 |
Why?
|
| Inflammation | 3 | 2019 | 10863 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 872 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 6514 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2952 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 545 | 0.070 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 899 | 0.070 |
Why?
|
| Animals | 14 | 2023 | 168939 | 0.070 |
Why?
|
| Temperature | 1 | 2013 | 2231 | 0.070 |
Why?
|
| Radiotherapy Dosage | 3 | 2021 | 2916 | 0.060 |
Why?
|
| Adiponectin | 1 | 2011 | 1121 | 0.060 |
Why?
|
| Arabinose | 1 | 2004 | 31 | 0.060 |
Why?
|
| Urogenital Abnormalities | 1 | 2008 | 255 | 0.060 |
Why?
|
| Lac Operon | 1 | 2004 | 237 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 1767 | 0.060 |
Why?
|
| DNA Nucleotidyltransferases | 1 | 2004 | 177 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 6359 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 5444 | 0.050 |
Why?
|
| Gallium Radioisotopes | 1 | 2023 | 195 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 6853 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2008 | 845 | 0.050 |
Why?
|
| Cytokines | 2 | 2021 | 7438 | 0.050 |
Why?
|
| Losartan | 1 | 2023 | 262 | 0.050 |
Why?
|
| Gene Library | 1 | 2004 | 1065 | 0.050 |
Why?
|
| Male | 12 | 2022 | 364154 | 0.050 |
Why?
|
| Apoptosis | 1 | 2018 | 9514 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2012 | 2903 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 17089 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2004 | 1525 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2022 | 20710 | 0.040 |
Why?
|
| Aged | 8 | 2022 | 171344 | 0.040 |
Why?
|
| Immunity, Innate | 2 | 2024 | 3079 | 0.040 |
Why?
|
| Collagen Type I | 1 | 2023 | 616 | 0.040 |
Why?
|
| Body Patterning | 1 | 2004 | 634 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2004 | 1524 | 0.040 |
Why?
|
| Clinical Trials as Topic | 3 | 2022 | 8045 | 0.040 |
Why?
|
| Plasmids | 1 | 2004 | 2268 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 2133 | 0.040 |
Why?
|
| Leucovorin | 1 | 2021 | 644 | 0.040 |
Why?
|
| Base Sequence | 2 | 2008 | 12415 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2024 | 734 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2012 | 3582 | 0.040 |
Why?
|
| Stem Cells | 1 | 2012 | 3536 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 9546 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2022 | 81657 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 11094 | 0.040 |
Why?
|
| Mutation | 2 | 2018 | 30214 | 0.040 |
Why?
|
| Ion Channels | 2 | 2012 | 1043 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2004 | 2669 | 0.030 |
Why?
|
| Molecular Imaging | 1 | 2023 | 822 | 0.030 |
Why?
|
| Tyrosine | 1 | 2001 | 1425 | 0.030 |
Why?
|
| Mitochondrial Proteins | 2 | 2012 | 980 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 59548 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2021 | 1652 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 11062 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 2930 | 0.030 |
Why?
|
| Cytoskeletal Proteins | 1 | 2001 | 1326 | 0.030 |
Why?
|
| Collagen | 1 | 2023 | 2635 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 3408 | 0.030 |
Why?
|
| Esophagus | 1 | 2021 | 1040 | 0.030 |
Why?
|
| Complement Factor D | 1 | 2014 | 67 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2008 | 7612 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2004 | 3446 | 0.030 |
Why?
|
| Complement C3a | 1 | 2014 | 66 | 0.030 |
Why?
|
| Female | 10 | 2022 | 396532 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 17609 | 0.030 |
Why?
|
| Disease Progression | 2 | 2021 | 13642 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2004 | 5795 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2022 | 54872 | 0.030 |
Why?
|
| Middle Aged | 5 | 2022 | 223267 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2023 | 2011 | 0.030 |
Why?
|
| Computational Biology | 1 | 2004 | 3564 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2004 | 4211 | 0.030 |
Why?
|
| Models, Biological | 2 | 2008 | 9464 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2013 | 23618 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2021 | 65286 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2013 | 1082 | 0.020 |
Why?
|
| Adipocytes, White | 1 | 2012 | 92 | 0.020 |
Why?
|
| Vaccination | 1 | 2024 | 3435 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 3213 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 501 | 0.020 |
Why?
|
| Mice, Knockout | 3 | 2014 | 14473 | 0.020 |
Why?
|
| Oncogenes | 1 | 2016 | 1232 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 12246 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 2902 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2012 | 371 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2013 | 1472 | 0.020 |
Why?
|
| Calcium | 1 | 2022 | 5783 | 0.020 |
Why?
|
| Embryo Loss | 1 | 2008 | 55 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1604 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2021 | 8728 | 0.020 |
Why?
|
| Phenotype | 2 | 2021 | 16722 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2008 | 163 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2021 | 6258 | 0.020 |
Why?
|
| Genetic Complementation Test | 1 | 2008 | 556 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 1718 | 0.020 |
Why?
|
| Radiation Protection | 1 | 2010 | 425 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2062 | 0.020 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 9528 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 4892 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2008 | 1751 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8540 | 0.010 |
Why?
|
| Prognosis | 2 | 2018 | 29959 | 0.010 |
Why?
|
| Incidence | 1 | 2022 | 21527 | 0.010 |
Why?
|
| DNA Primers | 1 | 2008 | 2826 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 40149 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2012 | 2856 | 0.010 |
Why?
|
| Embryonic Development | 1 | 2008 | 722 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2012 | 2573 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 36570 | 0.010 |
Why?
|
| Glucose | 1 | 2014 | 4340 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2008 | 2677 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 22351 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 1751 | 0.010 |
Why?
|
| Desmogleins | 1 | 2001 | 4 | 0.010 |
Why?
|
| Desmoglein 2 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Octoxynol | 1 | 2001 | 76 | 0.010 |
Why?
|
| gamma Catenin | 1 | 2001 | 45 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 11218 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2012 | 5890 | 0.010 |
Why?
|
| Desmoplakins | 1 | 2001 | 63 | 0.010 |
Why?
|
| Heterozygote | 1 | 2008 | 2795 | 0.010 |
Why?
|
| Pandemics | 1 | 2021 | 8734 | 0.010 |
Why?
|
| Detergents | 1 | 2001 | 235 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11876 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2014 | 3989 | 0.010 |
Why?
|
| Insulin | 1 | 2014 | 6608 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2008 | 4618 | 0.010 |
Why?
|
| COS Cells | 1 | 2001 | 1135 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2001 | 2168 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2001 | 1729 | 0.010 |
Why?
|
| Adult | 1 | 2013 | 223305 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2008 | 3610 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 3587 | 0.010 |
Why?
|
| Quality of Life | 1 | 2016 | 13476 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 11657 | 0.010 |
Why?
|
| Risk Factors | 1 | 2021 | 74889 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 12795 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 18329 | 0.000 |
Why?
|
| Cell Line | 1 | 2001 | 15564 | 0.000 |
Why?
|
| Pregnancy | 1 | 2008 | 30236 | 0.000 |
Why?
|